Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus

Sponsor
Atlas Biomed (Industry)
Overall Status
Completed
CT.gov ID
NCT04113239
Collaborator
(none)
200
1
24
8.4

Study Details

Study Description

Brief Summary

A case-control study to identify microbiome and genetic differences between healthy people and patients with incident type 2 diabetes mellitus.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: 16S rRNA gene sequencing
  • Genetic: DNA-microarray genotyping

Detailed Description

Two groups of people, one composed of healthy volunteers and the other of patients with incident type 2 diabetes mellitus who never received treatment for their condition, fill in the food frequency questionnaire and the physical activity questionnaire. DNA microarray genotyping is used to process the DNA samples of the participants. The data on the composition of the participants' gut microbiota is obtained through sequencing of their stool samples.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Actual Study Start Date :
Nov 27, 2019
Actual Primary Completion Date :
Oct 20, 2021
Actual Study Completion Date :
Nov 25, 2021

Arms and Interventions

Arm Intervention/Treatment
Diagnosed Type 2 Diabetes Mellitus

Patients with incident type 2 diabetes mellitus

Diagnostic Test: 16S rRNA gene sequencing
Taking a stool sample for gut microbiome DNA sequencing

Genetic: DNA-microarray genotyping
Taking a saliva sample for genotyping

Control

Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria

Diagnostic Test: 16S rRNA gene sequencing
Taking a stool sample for gut microbiome DNA sequencing

Genetic: DNA-microarray genotyping
Taking a saliva sample for genotyping

Outcome Measures

Primary Outcome Measures

  1. HbA1C [Baseline]

    Glycated hemoglobin level

  2. Glucose [Baseline]

    Fasting blood glucose level

  3. Gut microbiome composition of participants [Baseline]

    Bacteria abundance obtained via sequencing the DNA extracted from the stool sample

  4. Genotypes of participants [Baseline]

    Genotypes of thousands of SNPs obtained via DNA-microarray genotyping of the DNA extracted from the saliva sample

Secondary Outcome Measures

  1. Physical activity questionnaire [Baseline]

    Physical Activity Questionnaire. It collects information on physical activity comprising 16 questions grouped in four domains: activity at work (1), travel to and from places (2), recreational activities (3), sedentary behaviour (4).

  2. Food frequency questionnaire [12 months before baseline]

    Food frequency questionnaire assesses usual intake and portion size of more than 130 foods and beverages and more than 25 dietary supplements for the last 12 months. Responses are evaluated and analysed to compile a nutritional picture for each group of subjects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Confirmed diagnosis of incident type 2 diabetes mellitus
Exclusion Criteria:
  • Hypoglycaemic therapy prescribed for the correction of any type of hyperglycaemia

  • Diabetic ketoacidosis

  • Inflammatory bowel diseases (ulcerative colitis, Crohn's disease, coeliac disease)

  • Rheumatoid arthritis

  • Tuberculosis

  • Acute gastrointestinal conditions

  • Irritable bowel syndrome

  • Multiple intestinal polyposis

  • Gallstone disease

  • Acute pancreatitis

  • Oncological diseases

  • Serious mental disorders

  • Recent (< 6 months) antimicrobial therapy

  • Recent (< 3 months) proton pump inhibitors therapy

  • Recent (< 3 months) surgical intervention

  • Recent (< 3 weeks) use of probiotics, prebiotics, antacids, nonsteroidal anti-inflammatory drugs

  • Pregnancy or breastfeeding

  • Current alcohol/drug abuse or addiction within 12 months prior to screening

  • Planned relocation from the study area during the study

  • Other somatic pathologies or any factors that prevent the inclusion in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 City Clinical Hospital V.P. Demikhova Moscow Russian Federation

Sponsors and Collaborators

  • Atlas Biomed

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Atlas Biomed
ClinicalTrials.gov Identifier:
NCT04113239
Other Study ID Numbers:
  • T2D+FFQ/GPAQ/Genome/Metagenome
First Posted:
Oct 2, 2019
Last Update Posted:
Jul 20, 2022
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Atlas Biomed
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022